uniQure Announces Presentations at the 59th American Society of Hematology (ASH) Annual Meeting
November 01 2017 - 9:10AM
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company
advancing transformative therapies for patients with severe unmet
medical needs, today announced its company-sponsored clinical data
presentations at the 59th American Society of Hematology (ASH)
Annual Meeting, taking place in Atlanta, GA from December 9 to 12,
2017.
Poster Presentation
Title: |
|
Predictable Protein
Expression with Enhanced Factor IX Activity Following
Administration of a Modified AAV5-hFIX Vector to Nonhuman
Primates |
Presenter: |
|
Ying Poi Liu, Ph.D.,
senior scientist at uniQure |
Session
Name: |
|
801. Gene Therapy and
Transfer: Poster I |
Date: |
|
Saturday, December 9,
2017 |
Presentation
Time: |
|
5:30 PM - 7:30 PM EST |
Location: |
|
Georgia World Congress
Center, Building A, Level 1, Hall A2 |
The conference abstract was made available
today: ASH abstract.
A Good Laboratory Practices (GLP), nonclinical
study of AMT-061 has been performed in non-human primates at four
different dose levels up to a dose of 9 x 1013 gc/kg. The purpose
of this study was to compare AMT-061 to AMT-060 with respect to
liver transduction, circulating FIX protein levels, circulating FIX
activity levels and toxicity, after a single intravenous dose with
13- or 26-week observation periods.
Data from the study demonstrated a strong correlation between
dose and human FIX (hFIX) expression levels, as well as biological
activity of the expressed hFIX protein. At equal doses,
circulating vector DNA plasma levels, liver distribution, liver
cell transduction and hFIX protein expression were comparable for
both AMT-060 and AMT-061. Additionally, AMT-061 demonstrated
substantial increases in FIX clotting activity compared to AMT-060,
consistent with those previously reported for FIX-Padua.
Oral Presentation
Title: |
|
Stable Elevations in FIX
Activity and Reductions in Annualized Bleeding Rate over up to 2
Years of Follow-up of Adults with Severe or Moderate- Severe
Hemophilia B Treated with AMT-060 (AAV5-hFIX) Gene Therapy |
Presenter: |
|
Professor Frank W.G.
Leebeek, M.D. Ph.D. |
Session
Name: |
|
801. Gene Therapy and
Transfer: Gene Therapy for Hemophilia and Improving Lentiviral
Vectors |
Session
Date: |
|
Monday, December 11,
2017 |
Presentation Time: |
|
7:15 AM |
Location: |
|
Georgia World Congress
Center, Building C, Level 1, C101 Auditorium |
The conference abstract was made available
today: ASH abstract.
Long-term clinical data from the ongoing Phase
I/II trial of AMT-060 in patients with severe hemophilia B will be
presented on up to twenty-four months of follow-up. All ten
patients in the study demonstrated improvements in their disease
state as measured by reduced FIX replacement therapy and bleeding
frequency. Across the clinical trials’ two dosing cohorts,
cumulative annualized FIX consumption decreased by 79% as of
deadline for ASH abstract submission, and in the higher-dose cohort
of the study, no spontaneous bleeds were reported in the last six
months of follow-up - with a reduction in the annualized
spontaneous bleed rate of 84% compared to the one-year period prior
to gene transfer.
No patients developed inhibitors to FIX and
there were no detectable signs of sustained AAV5 capsid-specific
T-cell activation. Mild, temporary elevations in ALT were observed
in three patients, none of which were associated with changes in in
FIX activity or could be referred to as capsid-specific T-cell
responses. ALT elevations have not recurred.
About hemophilia B
Hemophilia B is a serious and rare inherited
disease in males characterized by insufficient blood clotting. The
condition can lead to repeated and sometimes life-threatening
episodes of external and internal bleeding following accidental
trauma or medical interventions. The episodes can cause long-term
damage, for example to the joints, and can be fatal if they occur
in the brain. The deficient blood clotting results from the lack of
functional human Factor IX, or hFIX. Treatment of hemophilia B
today consists of prophylactic or on-demand protein replacement
therapy, in which frequent intravenous administrations of
plasma-derived or recombinant hFIX are required to stop or prevent
bleeding. Hemophilia B occurs in approximately 1 out of 30,000 live
births.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary and partnered gene therapies to treat patients with
hemophilia, Huntington’s disease and cardiovascular diseases.
www.uniQure.com
uniQure Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such
as "anticipate," "believe," "could," "estimate," "expect," "goal,"
"intend," "look forward to", "may," "plan," "potential," "predict,"
"project," "should," "will," "would" and similar expressions.
Forward-looking statements are based on management's beliefs and
assumptions and on information available to management only as of
the date of this press release. These forward-looking statements
include, but are not limited to, the development of our gene
therapy product candidates, the success of our collaborations and
the risk of cessation, delay or lack of success of any of our
ongoing or planned clinical studies and/or development of our
product candidates, and the scope of protection provided by our
patent portfolio. Our actual results could differ materially from
those anticipated in these forward-looking statements for many
reasons, including, without limitation, risks associated with our
and our collaborators’ clinical development activities,
collaboration arrangements, corporate reorganizations and strategic
shifts, regulatory oversight, product commercialization and
intellectual property claims, as well as the risks, uncertainties
and other factors described under the heading "Risk Factors" in
uniQure’s Quarterly Report on Form 10-Q filed on November 1, 2017.
Given these risks, uncertainties and other factors, you should not
place undue reliance on these forward-looking statements, and we
assume no obligation to update these forward-looking statements,
even if new information becomes available in the future.
uniQure Contacts
For Investors:
Maria E. Cantor
Direct:
339-970-7536 Mobile: 617-680-9452
m.cantor@uniQure.com
Eva M. Mulder
Direct: +31
20 240 6103 Mobile:
+31 6 52 33 15 79e.mulder@uniQure.com
For Media:
Tom MaloneDirect:
339-970-7558Mobile: 339-223-8541t.malone@uniQure.com
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Mar 2024 to Apr 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2023 to Apr 2024